-transparent.png){kind=logo}
The authors report a case of fatal Daunorubicin cardiotoxicity on initial phase of therapy for Acute Myeloblastic Leukemia at cumulative doses (225 mg/mq) considered still safe from the current literature. Despite the interruption of therapy and the interventions performed in support of cardiac functionality the patient came to exitus for heart failure 24 hours after the symptoms onset. This example represents a further confirmation of the utility of a steady monitoring with specific tests for the patients undergoing Daunorubicin therapy.
Related Publications
C Rizzari, and
M Santamaria, and
M A Galli, and
M Jankovic, and
C Uderzo
October 1972,
Ugeskrift for laeger,
C Rizzari, and
M Santamaria, and
M A Galli, and
M Jankovic, and
C Uderzo
March 1982,
Gan to kagaku ryoho. Cancer & chemotherapy,
C Rizzari, and
M Santamaria, and
M A Galli, and
M Jankovic, and
C Uderzo
January 1994,
[Rinsho ketsueki] The Japanese journal of clinical hematology,
C Rizzari, and
M Santamaria, and
M A Galli, and
M Jankovic, and
C Uderzo
January 1986,
The American journal of pediatric hematology/oncology,
C Rizzari, and
M Santamaria, and
M A Galli, and
M Jankovic, and
C Uderzo
March 2002,
Cancer genetics and cytogenetics,
C Rizzari, and
M Santamaria, and
M A Galli, and
M Jankovic, and
C Uderzo
January 1995,
The Turkish journal of pediatrics,
C Rizzari, and
M Santamaria, and
M A Galli, and
M Jankovic, and
C Uderzo
December 2009,
Turkish journal of haematology : official journal of Turkish Society of Haematology,
C Rizzari, and
M Santamaria, and
M A Galli, and
M Jankovic, and
C Uderzo
August 1991,
Khirurgiia,
C Rizzari, and
M Santamaria, and
M A Galli, and
M Jankovic, and
C Uderzo
April 1987,
[Rinsho ketsueki] The Japanese journal of clinical hematology,
C Rizzari, and
M Santamaria, and
M A Galli, and
M Jankovic, and
C Uderzo
July 2015,
Cell biochemistry and biophysics,
